Topics in Companion Animal Medicine
Volume 25, Issue 1 , Pages 32-44 , February 2010

Oncology Pain in Veterinary Patients

  • Andrea Looney, DVM, DACVA

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Andrea Looney, DVM, DACVA, Cornell University Hospital for Animals, Cornell University, Ithaca, NY 14853

References 

  1. Bonica JJ, Ventafridda V, Twycross RG. Cancer pain. In:  Bonica JJ editors. The Management of Pain. ed 2. Philadelphia: Lea and Feibiger; 1990;p. 400–401
  2. Caraceni A. Clinicipathological correlates of common cancer pain syndrome. Hematol Oncol Clin North Am. 1996;10:57–62
  3. Merkskey H, Bogduk N. Classification of Chronic Pain. ed 2. Seattle: IASP Press; 1994;
  4. Bruera E, Macmillan K, Hanson J, et al. The Edmonton staging system for cancer pain: preliminary report. Pain. 1989;37:203–209
  5. Eidelman A, Carr DB. Taxonomy of cancer pain. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 3–12
  6. Nicholson B. Taxonomy of pain. Clin J Pain. 2000;16:S114–S117
  7. Wojciechowska JI, Hewson CJ, Stryhn H, et al. Evaluation of a questionnaire regarding nonphysical aspects of quality of life in sick and healthy dogs. Am J Vet Res. 2005;66(8):1461–1467
  8. Yazbek KVB, Fantoni DT. Validity of a health-related quality-of-life scale for dogs with signs of pain secondary to cancer. J Am Vet Med Assoc. 2005;226(8):1354–1358
  9. Brown DC, Boston RC, Coyne JC. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631–637
  10. Tzannes S, Hammond MF, Murphy S. Owners ‘perception of their cats’ quality of life during COP chemotherapy for lymphoma. J Feline Med Surg. 2008;10(1):73–81
  11. Driver LC, Cata JP, Phan PC. Peripheral neuropathy due to chemotherapy and radiation therapy. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 25–27
  12. Willard MD. Canine and feline chronic diarrheas. In: Proceedings of the American College of Veterinary Internal Medicine. 2009;p. 241–242
  13. Carr AP. Managing constipation in cats. In: Proceedings of the American College of Veterinary Internal Medicine. 2009;p. 246–247
  14. Leib MS, Duncan RB. Gastric Helicobacter spp. and chronic vomiting in dogs. In:  Bonagura JD,  Twedt DC editor. Kirk's Current Veterinary Therapy XIV. St Louis: Saunders Elsevier; 2009;p. 492–494
  15. Cohn LA. Hormone-responsive urinary incontinence. In:  Cote E editors. Clinical Veterinary Advisor; 2007;p. 531–532
  16. Durocher LL, Chew DJ. Diseases of urinary bladder. In:  Morgan RV editors. Handbook of Small Animal Practice. St. Louis, MO: Saunders Elsevier; 2008;p. 526–550
  17. Allard P, Maunsell E, Labbe J, et al. Educational interventions to improve cancer pain control: a systematic review. J Palliat Med. 2001;4:191–203
  18. Dawkins MS. The science of suffering. In:  McMillan FD editors. Mental Health and Well-being in Animals. Ames, Iowa: Blackwell; 2005;p. 47–56
  19. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18
  20. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524–1534
  21. Roudebush P, Davenport DJ, Novotny BJ. The use of nutraceuticals in cancer therapy. Vet Clin Small Anim North Am. 2004;34:249–269
  22. Davenport DJ: The Use of Dietary Polyunsaturated Fatty Acids in the Management of Cancer Patients. Proceedings of the American College of Veterinary Internal Medicine, 2003
  23. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev. 2007;33:407–418
  24. Fryer RA, Galustian C, Dalgelish AG, et al. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol. 2009;4(2):102–112
  25. Sagar J, Sales K, Dijk S, et al. Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?. World J Surg Oncol. 2009;7:2
  26. Khanna C. Novel treatment options for the veterinary cancer patient. Proceedings of the World Small Animal Veterinary Association Congress http://www.vin.com2005;
  27. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005;55:319–321
  28. Moss RW. Do antioxidants interfere with radiation therapy for cancer?. Integrative Cancer Ther. 2007;6:281–292
  29. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Agents. 2002;2(6):691–714
  30. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther. 2001;90(2-3):157–177
  31. Beauchamp GK, Keast RS, Morel D, et al. Ibuprofen-like activity in extra-virgin olive oil. Nature. 2005;437:45–46
  32. Mendelson FA, Divino CM, Reis ED, et al. Wound care after radiation therapy. Adv Skin Wound Care. 2002;15:216–224
  33. Belcher AE, Selekof J. Skin care for the oncology patient. In:  Krasner DL,  Rodeheaver GT,  Sibbald RG editor. Chronic Wound Care: A Clinical Source Book for Healthcare Professionals. ed 3. Philadelphia: HMP Communications; 2001;p. 711–720
  34. Trepanier LA: Transdermal drugs: an update. Proceedings of the American Association of Feline Practitioners, Winter Meeting 2007
  35. Fransson BA, Peck KE, Smith JK, et al. Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. Am J Vet Res. 2002;63(9):1309–1312
  36. Willis-Goulet HS, Schmidt BA, Nicklin CF, et al. Comparison of serum dexamethasone concentrations in cats after oral or transdermal administration using pluronic lecithin organogel (PLO): a pilot study. Vet Dermatol. 2003;14:83–89
  37. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the US, 1990-1997: results of a follow up national survey. J Am Med Assoc. 1998;280:1569–1575
  38. MacPherson H, Thomas K, Walters S, et al. A prospective survey of adverse events and treatment reactions following 34,000 consultations with professional acupuncturists. Acupunct Med. 2001;19:93–102
  39. Sliwa JA, Marciniak C. Physical rehabilitation of the cancer patient. Cancer Treat Res. 1999;100:75–89
  40. Mortimer PS, Badger C, Hall JG. Lymphoedema. In:  Doyle D,  Hankds GWC,  MacDonald N editor. Oxford Textbook of Palliative Medicine. ed 2. New York: Oxford University Press; 1998;p. 657–660
  41. Mays TA. Tricyclic antidepressants. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 305–310
  42. Magni G, Arsie D, De Leo D. Antidepressants in the treatment of cancer pain: a survey in Italy. Pain. 1987;29:347–353
  43. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatr Neurosci. 2001;26:30–36
  44. Zinder O, Dar DE. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol Scand. 1999;167(3):181–188
  45. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81–110
  46. Harris RE, Beebe Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep. 2005;13(4):559–583
  47. Abdel-Tawab M, Zettl H, Schubert-Zsilavecz M. Nonsteroidal anti-inflamamtory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem. 2009;16(16):2042–2063
  48. Bonnefont J, Courade JP, Alloui A, et al. Mechanism of the antinociceptive effect of paracetamol. Drugs. 2003;63:1–4
  49. Lucas R, Warner TD, Vojnovic I, et al. Cellular mechanisms of acetaminophen: role of cyclooxygenase. FASEB J. 2005;19:635–637
  50. Graham GC, Scott KF. Mechanism of action of paracetamol. Am J Ther. 2005;12:46–55
  51. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997;54:643–652
  52. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. 2008;31(3):187–199
  53. Hale M, Upmalis D, Okamoto A. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25(5):1095–1104
  54. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 2000;20:358–373
  55. Lascelles BDX, Gaynor JS, Smith ES. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Intern Med. 2008;22(1):53–59
  56. Gorman Al, Elliott KS, Inturrisi CE. The isomers of methadone bind to the non-competitive site on the NMDA receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223:5–8
  57. Leng G, Finnegan MS. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med. 1994;8:153–155
  58. Wallace MS. Sodium and calcium channel antagonists. In:  Wallace MS,  Staats PS editor. Pain Medicine and Management: Just the Facts. New York: McGraw Hill; 2005;p. 59–63
  59. Caracas HC, Maciel JV, Martins PM. The use of lidocaine as an anti-inflammatory substance: a systematic review. J Dent. 2009;37(2):93–97
  60. Bennett MI. Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain. 1997;70:93–94
  61. Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000;25:274–278
  62. Collins R, Lieberburg I, Ludington , et al. Effectiveness of intrathecal ziconotide in multiple pain etiologies: a meta-analysis of three controlled trials (In American Academy of Pain Medicine Annual Meeting Abstracts). Pain Med. 2005;6:165–197
  63. Chard PS, Bleakman D, Savidge JR, et al. Capsaicin-induced neurotoxicity in cultured dorsal root ganglion neurons: involvement of calcium-activated proteases. Neuroscience. 1995;65:1099–1108
  64. Kissin EY, Freitas CF, Kissin I. The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis. Anesth Analg. 2005;101(5):1433–1439
  65. Brown DC, Iadarola MJ, Perkowski SZ. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103(5):1052–1059
  66. McGeeney BE. Anticonvulsants. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 317–325
  67. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400
  68. Smirne S, Scarlato G. Clonazepam in cranial neuralgias. Med J Aust. 1977;1:93–94
  69. Robertson SA, Lascelles BD, Taylor PM, et al. PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration. J Vet Pharmacol Ther. 2005;28(5):453–460
  70. Egger CM, Glerum L, Haag KM, et al. Efficacy and cost-effectiveness of transdermal fentanyl patches for the relief of post-operative pain in dogs after anterior cruciate ligament and pelvic limb repair. Vet Anaesth Analg. 2007;34(3):200–208
  71. Chandler S. Nebulized opioids to treat dyspnea. Am J Hosp Palliat Care. 1999;16:418–422
  72. Pavis H, Wilcock A, Edgecombe J, et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in cancer patients. J Pain Symptom Manage. 2002;24:598–602
  73. Vascello L, McQuillan RJ. Opioid analgesics and routes of administration. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 171–191
  74. Eisenach JC, DeKock M, Klimscha W. Alpha2 adrenergic agonists for regional anesthesia (A clinical review of clonidine (1984-1995)). Anesthesiology. 1996;85:655–674
  75. Waxman SG, Dib-Hajj S, Cummins TR, et al. Sodium channels and pain. Proc Natl Acad Sci USA. 1999;96:7635
  76. Brill S, Sedgwick PM, Hamann W, et al. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth. 2002;89:711
  77. Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Acta Oncol. 1996;35:50–55
  78. Grabow T. Intravenous drug infusions. In:  Wallace MS,  Staats PS editor. Pain Medicine and Management: Just the Facts. New York: McGraw Hill; 2005;
  79. White C, Rajagopal A. Intraspinal therapy. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 417–427
  80. Gilfor JM, Viscusi ER. Epidural analgesia. In:  Wallace MS,  Staats PS editor. Pain Medicine and Management: Just the Facts. New York: McGraw Hill; 2005;p. 85–88
  81. Hassenbusch SJ, Stanton-Hicks M, Covington E, et al. Long term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage. 1995;10:527–529
  82. Krames ES. Intrathecal infusion therapies for intractable pain: patient management guidelines. J Pain Symptom Manage. 1993;8:36–38
  83. North RB. Spinal cord stimulation. In:  Wallace MS,  Staats PS editor. Pain Medicine and Management: Just the Facts. New York: McGraw Hill; 2005;p. 285–288
  84. Schon LC, Davies PW. Peripheral nerve stimulation. In:  Wallace MS,  Staats PS editor. Pain Medicine and Management: Just the Facts. New York: McGraw Hill; 2005;p. 315–316
  85. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893–899
  86. Archangeli G, Micheli A, Arcangeli G, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol. 1989;14:95–101
  87. Cousins MJ, Dwyer B, Gibb D. Chronic pain and neurolytic neural blockade. In:  Cousins MJ,  Bridenbaugh PO editor. Neural Blockade in Clinical Anesthesia and Management of Pain. ed 2. Philadelphia: JB Lippincott; 1988;p. 1053–1064
  88. Saberski L, Fitzgerald J, Ahmad M. Cryoneurolysis and radiofrequency lesioning. In:  Raj PP editors. Practical Management of Pain. St Louis: Mosby; 2000;p. 759
  89. Janjan N. Bone metastases: approaches to management. Semin Oncol. 2001;28(suppl 11):28–34
  90. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vetebroplasty and kyphoplasty for painful vertebral compression fractures in cancer patients. J Neurosurg. 2003;98:21–30
  91. Fenstermaker RA. Neurosurgical procedures for cancer pain management. In: de Leon-Casasola  editors. Cancer Pain: Pharmacological, Interventional and Palliative Care Approaches. Philadelphia: Saunders; 2006;p. 453–458

PII: S1938-9736(09)00084-1

doi: 10.1053/j.tcam.2009.10.008

Topics in Companion Animal Medicine
Volume 25, Issue 1 , Pages 32-44 , February 2010

Article Tools

* Image Usage & Resolution